<DOC>
	<DOCNO>NCT01055496</DOCNO>
	<brief_summary>This phase 1 trial design evaluate safety tolerability chemotherapy combination inotuzumab ozogamicin , investigational product , adults CD22-positive non-Hodgkin 's lymphoma . The trial involve two arm . In one arm , subject receive chemotherapy regimen R-CVP ( rituximab , cyclophosphamide , vincristine prednisone ) . In arm , subject receive R-GDP ( rituximab , gemcitabine , cisplatinum dexamethasone ) . Subjects arm also receive inotuzumab ozogamicin .</brief_summary>
	<brief_title>Study Evaluating Chemotherapy Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>Dose escalation cohort : subject diagnosis CD22positive NonHodgkin 's Lymphoma ( NHL ) least 1 prior anticancer treatment , include prior treatment rituximab chemotherapy . Expanded maximum tolerate dose ( MTD ) confirmation preliminary efficacy cohort : subject diagnosis CD22positive NHL least 1 prior anticancer treatment , include prior treatment rituximab chemotherapy newly diagnose subject candidate anthracyclinebased therapy . At least 1 measurable disease lesion &gt; 1 cm long transverse diameter , product diameter &gt; 2.25 cm2 CT magnetic resonance imaging ( MRI ) . Candidate potentially curative therapy stem cell transplantation . Prior allogeneic hematopoietic stem cell transplantation ( HSCT ) . Prior autologous transplantation , radioimmunotherapy , anti CD22 immunotherapy &lt; = 6 month first dose investigational product . More 3 previous combination chemotherapy ( 2 cytotoxics ) anticancer regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
</DOC>